Astex Pharmaceuticals, Inc. Message Board
-
ASH Abstracts Are Out
SGI-110 results look ok. Nothing spectacular. Nothing on AT 7519. Hmmmm
-
Ash had some good things. First dacogen works for 8 hours, the half life is 4x dacogens,they are seeing improved PK profile over dacogen with sgi-110.
The AE's are reporting is superior to dacogen 85% of dacogen pts suffer to lower platelet counts after taking the drug. SGI-110 only 8%. I think strong platelet counts is a good thing.
With dacogen 87% see a immunosuppressed and risk infections, with sgi-110 this drops to 27% of pts.
I believe a strong immune system is a good thing. This way sgi-110 doesn't have to do all the work. Vidaza AE's are even greater than dacogens, so this may point at a better drug than Vidaza? We'll have to see.Sentiment: Strong Buy
- 2 Replies to freetoquestionu
-
Free, you think that Vidaza outsells Dac in US because of a better marketing team at Celgene or another reason? Reason I ask is because of the comment about Vidaza where you say it has greater AE's than Dac. Market share has been the same for the last 3/4 years from what I remember.
-
First dacogen works for 8 hours, the half life is 4x dacogens,they are seeing improved PK profile over dacogen with sgi-110
Wasn't this a given situation back in July in there finding ? So why are you talking about something that is old news
With dacogen 87% see a immunosuppressed and risk infections, with sgi-110 this drops to 27% of pts
So this is what you've been waiting for and your price target of $25, are you on crack.?
-
Test
Sentiment: Strong Buy
-